10don MSN
Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
Q1 2026 Management View "In April, we completed an oversubscribed public offering resulting in $225 million in gross proceeds" and "the proceeds from the April offering, along with our existing funds, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results